Main |
Browse Volumes |
Forthcoming Volumes |
Annals PrePrints |
Annals Extra |
E-mail Alerts |
Subscriptions & Orders |
New Proposals |
Author Guidelines |
About Annals |
Help |
 |
|
|
|
|
|
Part III. Targeting Components of the Stress System as Potential Therapies |
Serotonin and Norepinephrine Reuptake Inhibition and Eating Behavior
VOJTECH HAINERa,
KAROLINA KABRNOVAa,
BASHAR ALDHOONa,
MARIE KUNESOVAa AND
MARTIN WAGENKNECHTa
a Institute of Endocrinology, Obesity Management Center, 11694 Prague 1, Czech Republic
Key Words: serotonin • norepinephrine • eating behavior • dietary disinhibition • sibutramine • abdominal obesity • metabolic syndrome
Address for correspondence: Dr. Vojtech Hainer, Institute of Endocrinology, Narodni 8, 116 94 Prague 1, Czech Republic. Voice: 00420-724211155; fax: 00420-224905325. e-mail: vhainer{at}endo.cz
Brain neurotransmitters, serotonin and norepinephrine, play an important role in the central nervous control of energy balance and are involved in symptomatology related to both obesity and depression. Therefore both serotonin and norepinephrine neural pathways have been paid a special attention as targets for the antiobesity drugs, antidepressants, and drugs used in the treatment of eating disorders. Selective serotonin reuptake inhibitors (SSRI) have been used in the treatment of depression and eating disorders but have failed to achieve sustained weight loss in the treatment of obesity. Sibutramine, a serotonin and norepinephrine reuptake inhibitor, which induces satiety and prevents decline in metabolic rate associated with a hypocaloric diet, is currently the sole centrally acting drug indicated for the long-term treatment of obesity. Depression, dietary disinhibition (evaluated by the Eating Inventory [EI]), and stress are associated with the accumulation of abdominal fat and the development of metabolic syndrome and related diseases. Subjects with abdominal obesity demonstrate neuroendocrine abnormalities which result in disturbances in hypothalamo-pituitary-adrenal (HPA) function. Treatment with SSRI might interrupt the vicious circle which leads to endocrine abnormalities and the accumulation of abdominal fat. Obesity treatment with sibutramine results, not only in significant weight loss, but also in reduction of abdominal fat and in the improvement of health risks associated with metabolic syndrome (lipid profile, blood glucose, insulin, HbA1c, and uric acid), as well as in the decline in disinhibition score of the EI. In a 1-year sibutramine trial, only a decrease in the disinhibition score remained a significant correlate of weight loss among the psychobehavioral and nutritional factors which were taken into account.
This article has been cited by other articles:
|
|
|
|
 
A. M. Sharma
A weighty issue: Medication as a cornerstone of medical obesity management
Can Fam Physician,
April 1, 2008;
54(4):
498 - 499.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Sharma
Question lourde de consequences: La medication comme base de la prise en charge medicale de l'obesite
Can Fam Physician,
April 1, 2008;
54(4):
500 - 501.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Tizzano, D. S. Stribling, D. Perez-Tilve, A. Strack, A. Frassetto, R. Z. Chen, T. M. Fong, L. Shearman, P. A. Krieter, M. H. Tschop, et al.
The Triple Uptake Inhibitor (1R,5S)-(+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0] Hexane Hydrochloride (DOV 21947) Reduces Body Weight and Plasma Triglycerides in Rodent Models of Diet-Induced Obesity
J. Pharmacol. Exp. Ther.,
March 1, 2008;
324(3):
1111 - 1126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sookoian and C. J. Pirola
Review: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications
Therapeutic Advances in Cardiovascular Disease,
October 1, 2007;
1(1):
37 - 47.
[Abstract]
[PDF]
|
|
|
|
